1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
2
|
Peinert S, Grothe W, Stein A, Müller LP,
Ruessel J, Voigt W, Schmoll HJ and Arnold D: Safety and efficacy of
weekly 5-fluorouracil/folinic acid/oxaliplatin/irinotecan in the
first-line treatment of gastrointestinal cancer. Ther Adv Med
Oncol. 2:161–174. 2010. View Article : Google Scholar : PubMed/NCBI
|
3
|
Stein U, Walther W, Arlt F, Schwabe H,
Smith J, Fichtner I, Birchmeier W and Schlag PM: MACC1, a newly
identified key regulator of HGF-MET signaling, predicts colon
cancer metastasis. Nat Med. 15:59–67. 2009. View Article : Google Scholar : PubMed/NCBI
|
4
|
Lin L, Huang H and Liao W, Ma H, Liu J,
Wang L, Huang N, Liao Y and Liao W: MACC1 supports human gastric
cancer growth under metabolic stress by enhancing the Warburg
effect. Oncogene. 34:2700–2710. 2015. View Article : Google Scholar : PubMed/NCBI
|
5
|
Wang L, Wu Y, Lin L, Liu P, Huang H, Liao
W, Zheng D, Zuo Q, Sun L, Huang N, et al: Metastasis-associated in
colon cancer-1 upregulation predicts a poor prognosis of gastric
cancer, and promotes tumor cell proliferation and invasion. Int J
Cancer. 133:1419–1430. 2013. View Article : Google Scholar : PubMed/NCBI
|
6
|
Djiogue S, Kamdje Nwabo AH, Vecchio L,
Kipanyula MJ, Farahna M, Aldebasi Y and Seke Etet PF: Insulin
resistance and cancer: The role of insulin and insulin-like growth
factors. Endocr Relat Cancer. 20:R1–R17. 2013. View Article : Google Scholar : PubMed/NCBI
|
7
|
Hiller K and Metallo CM: Profiling
metabolic networks to study cancer metabolism. Curr Opin
Biotechnol. 24:60–68. 2013. View Article : Google Scholar : PubMed/NCBI
|
8
|
Tamada M, Nagano O, Tateyama S, Ohmura M,
Yae T, Ishimoto T, Sugihara E, Onishi N, Yamamoto T, Yanagawa H, et
al: Modulation of glucose metabolism by CD44 contributes to
antioxidant status and drug resistance in cancer cells. Cancer Res.
72:1438–1448. 2012. View Article : Google Scholar : PubMed/NCBI
|
9
|
Zhang Y and Yang JM: Altered energy
metabolism in cancer: A unique opportunity for therapeutic
intervention. Cancer Biol Ther. 14:81–89. 2013. View Article : Google Scholar : PubMed/NCBI
|
10
|
Liu H, Wu X, Dong Z, Luo Z, Zhao Z, Xu Y
and Zhang JT: Fatty acid synthase causes drug resistance by
inhibiting TNF-α and ceramide production. J Lipid Res. 54:776–785.
2013. View Article : Google Scholar : PubMed/NCBI
|
11
|
Yang Y, Liu H, Li Z, Zhao Z, Yip-Schneider
M, Fan Q, Schmidt CM, Chiorean EG, Xie J, Cheng L, et al: Role of
fatty acid synthase in gemcitabine and radiation resistance of
pancreatic cancers. Int J Biochem Mol Biol. 2:89–98.
2011.PubMed/NCBI
|
12
|
Wangpaichitr M, Sullivan EJ,
Theodoropoulos G, Wu C, You M, Feun LG, Lampidis TJ, Kuo MT and
Savaraj N: The relationship of thioredoxin-1 and cisplatin
resistance: Its impact on ROS and oxidative metabolism in lung
cancer cells. Mol Cancer Ther. 11:604–615. 2012. View Article : Google Scholar : PubMed/NCBI
|
13
|
Menendez JA and Lupu R: Fatty acid
synthase and the lipogenic phenotype in cancer pathogenesis. Nat
Rev Cancer. 7:763–777. 2007. View
Article : Google Scholar : PubMed/NCBI
|
14
|
Kuhajda FP: Fatty-acid synthase and human
cancer: New perspectives on its role in tumor biology. Nutrition.
16:202–208. 2000. View Article : Google Scholar : PubMed/NCBI
|
15
|
Xiang HG, Hao J, Zhang WJ, Lu WJ, Dong P,
Liu YB and Chen L: Expression of fatty acid synthase negatively
correlates with PTEN and predicts peritoneal dissemination of human
gastric cancer. Asian Pac J Cancer Prev. 16:6851–6855. 2015.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Hashimoto T, Kusakabe T, Sugino T, Fukuda
T, Watanabe K, Sato Y, Nashimoto A, Honma K, Kimura H, Fujii H, et
al: Expression of heart-type fatty acid-binding protein in human
gastric carcinoma and its association with tumor aggressiveness,
metastasis and poor prognosis. Pathobiology. 71:267–273. 2004.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Duan J, Sun L, Huang H, Wu Z, Wang L and
Liao W: Overexpression of fatty acid synthase predicts a poor
prognosis for human gastric cancer. Mol Med Rep. 13:3027–3035.
2016.PubMed/NCBI
|
18
|
Shiragami R, Murata S, Kosugi C, Tezuka T,
Yamazaki M, Hirano A, Yoshimura Y, Suzuki M, Shuto K and Koda K:
Enhanced antitumor activity of cerulenin combined with oxaliplatin
in human colon cancer cells. Int J Oncol. 43:431–438.
2013.PubMed/NCBI
|
19
|
Liu H, Liu Y and Zhang JT: A new mechanism
of drug resistance in breast cancer cells: Fatty acid synthase
overexpression-mediated palmitate overproduction. Mol Cancer Ther.
7:263–270. 2008. View Article : Google Scholar : PubMed/NCBI
|
20
|
Bauerschlag DO, Maass N, Leonhardt P,
Verburg FA, Pecks U, Zeppernick F, Morgenroth A, Mottaghy FM, Tolba
R, Meinhold-Heerlein I, et al: Fatty acid synthase overexpression:
Target for therapy and reversal of chemoresistance in ovarian
cancer. J Transl Med. 13:1462015. View Article : Google Scholar : PubMed/NCBI
|
21
|
Warburg O: On the origin of cancer cells.
Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
|
22
|
Menendez JA: Fine-tuning the
lipogenic/lipolytic balance to optimize the metabolic requirements
of cancer cell growth: Molecular mechanisms and therapeutic
perspectives. Biochim Biophys Acta. 1801:381–391. 2010. View Article : Google Scholar : PubMed/NCBI
|
23
|
Furuta E, Okuda H, Kobayashi A and Watabe
K: Metabolic genes in cancer: Their roles in tumor progression and
clinical implications. Biochim Biophys Acta. 1805:141–152.
2010.PubMed/NCBI
|
24
|
Sun L, Duan J, Jiang Y, Wang L, Huang N,
Lin L, Liao Y and Liao W: Metastasis-associated in colon cancer-1
upregulates vascular endothelial growth factor-C/D to promote
lymphangiogenesis in human gastric cancer. Cancer Lett.
357:242–253. 2015. View Article : Google Scholar : PubMed/NCBI
|
25
|
Hopperton KE, Duncan RE, Bazinet RP and
Archer MC: Fatty acid synthase plays a role in cancer metabolism
beyond providing fatty acids for phospholipid synthesis or
sustaining elevations in glycolytic activity. Exp Cell Res.
320:302–310. 2014. View Article : Google Scholar : PubMed/NCBI
|
26
|
Chang L, Wu P, Senthilkumar R, Tian X, Liu
H, Shen X, Tao Z and Huang P: Loss of fatty acid synthase
suppresses the malignant phenotype of colorectal cancer cells by
down-regulating energy metabolism and mTOR signaling pathway. J
Cancer Res Clin Oncol. 142:59–72. 2016. View Article : Google Scholar : PubMed/NCBI
|
27
|
Zhang D and Fan D: New insights into the
mechanisms of gastric cancer multidrug resistance and future
perspectives. Future Oncol. 6:527–537. 2010. View Article : Google Scholar : PubMed/NCBI
|
28
|
Chen ZM, Shi HR, Li X, Deng YX and Zhang
RT: Downregulation of MACC1 expression enhances cisplatin
sensitivity in SKOV-3/DDP cells. Genet Mol Res. 14:17134–17144.
2015. View Article : Google Scholar : PubMed/NCBI
|
29
|
Zhang R, Shi H, Ren F, Li X, Zhang M, Feng
W and Jia Y: Knockdown of MACC1 expression increases cisplatin
sensitivity in cisplatin-resistant epithelial ovarian cancer cells.
Oncol Rep. 35:2466–2472. 2016.PubMed/NCBI
|
30
|
Hilvo M, Denkert C, Lehtinen L, Müller B,
Brockmöller S, Seppänen-Laakso T, Budczies J, Bucher E, Yetukuri L,
Castillo S, et al: Novel theranostic opportunities offered by
characterization of altered membrane lipid metabolism in breast
cancer progression. Cancer Res. 71:3236–3245. 2011. View Article : Google Scholar : PubMed/NCBI
|